- Home
- ARCT vs ALEC Comparison
ARCT vs ALEC Comparison
Compare ARCT & ALEC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ARCT | ALEC |
|---|---|---|
| Founded | 2013 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 198.1M | 158.8M |
| IPO Year | 2019 | 2019 |
Fundamental Metrics
Financial Performance| Metric | ARCT | ALEC |
|---|---|---|
| Price | $5.52 | $1.50 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 10 | 6 |
| Target Price | ★ $24.11 | $4.83 |
| AVG Volume (30 Days) | 564.0K | ★ 772.7K |
| Earning Date | 05-07-2026 | 05-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 20.00 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $82,031,000.00 | $21,045,000.00 |
| Revenue This Year | N/A | $2.03 |
| Revenue Next Year | $12.77 | $29.87 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $5.74 | $1.09 |
| 52 Week High | $24.14 | $3.40 |
Technical Indicators
Market Signals| Indicator | ARCT | ALEC |
|---|---|---|
| Relative Strength Index (RSI) | 26.97 | 39.93 |
| Support Level | N/A | $1.37 |
| Resistance Level | $7.98 | $1.60 |
| Average True Range (ATR) | 0.36 | 0.12 |
| MACD | -0.10 | -0.01 |
| Stochastic Oscillator | 0.23 | 20.83 |
Price Performance
Historical ComparisonAbout ARCT Arcturus Therapeutics Holdings Inc.
Arcturus Therapeutics Holdings Inc is an RNA medicines company focused on the development of infectious disease vaccines and opportunities within liver and respiratory rare diseases. It operates in one business segment, which includes all activities related to the discovery, development, and commercialization of messenger RNA medicines. The company's pipeline includes LUNAR-OTC and LUNAR-CF. Its Vaccine candidates include LUNAR-FLU, KOSTAIVE XBB.1.5, KOSTAIVE, and Others.
About ALEC Alector Inc.
Alector Inc is a clinical-stage biotechnology company focused on developing therapies for neurodegenerative diseases. The company advances a pipeline of product candidates including Nivisnebart (AL101/GSK4527226) for Alzheimer's disease, AL137 for Alzheimer's disease, AL050 for Parkinson's disease and Lewy body dementia, and AL064, an siRNA program targeting tau for Alzheimer's disease and other tauopathies, supported by its proprietary Alector Brain Carrier (ABC) platform designed to improve delivery of therapeutics across the blood-brain barrier.